


PRODUCT INFORMATION

Oligomycin Complex

Item No. 11341

CAS Registry No.: 1404-19-9
MF: C₄₅H₇₄O₁₁ (Oligomycin A)
 C₄₅H₇₂O₁₂ (Oligomycin B)
 C₄₅H₇₄O₁₀ (Oligomycin C)
FW: 791.1 (Oligomycin A)
 805.1 (Oligomycin B)
 775.1 (Oligomycin C)
Purity: ≥95% (Mixture of A, B, C)
UV/Vis.: λ_{max}: 225 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oligomycin complex is supplied as a crystalline solid. A stock solution may be made by dissolving the oligomycin complex in the solvent of choice. Oligomycin complex is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of oligomycin complex in ethanol and DMF is approximately 30 mg/ml and 20 mg/ml in DMSO.

Oligomycin complex is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, oligomycin complex should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Oligomycin complex has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Oligomycins are macrolides created by *Streptomyces* species that can be toxic to other organisms through their ability to inhibit mitochondrial membrane-bound ATP synthases. The mitochondrial F₁F₀ ATP synthase can switch to an ATP hydrolase during ischemia, so that, under these conditions, inhibition by oligomycins will reduce ATP depletion rather than block ATP synthesis.¹ Oligomycin complex is a mixture of oligomycins A (Item No. 11342), B (Item No. 11343), and C. Oligomycin A is a selective inhibitor of mitochondrial F₁F₀-ATP synthase that induces apoptosis in a variety of cell types (average GI₅₀ = 270 nM).²⁻⁴ Oligomycin B is a nonselective inhibitor of ATP synthases. Oligomycin B (1-10 μM) can reduce the rate of ATP depletion in myocardial ischemia and decrease calcium-induced calcium release oscillation frequency of rat sensory neurons.^{1,5}

References

1. Grover, G.J. and Malm, J. *Cardiovasc. Ther.* **26**, 287-296 (2008).
2. Salomon, A.R., Voehringer, D.W., *Chem. Biol.* **8**, 71-80 (2001).
3. Shin, Y.-K., Yoo, B.C., Chang, H.J., *et al. Cancer Res.* **65**(8), 3162-3170 (2005).
4. Laatsch, H., Kellner, M., Wolf, G., *et al. J. Antibiot.* **46**(9), 1334-1341 (1993).
5. Jackson, J.G. and Thayer, S.A. *J. Neurophysiol.* **96**, 1093-1104 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM